Epidemiology and Treatment Modalities for BPH Epidemiology and Treatment Modalities for BPH

A new review provides insight into the epidemiology of benign prostatic hyperplasia and explores the currently available treatment options for this condition.Translational Andrology and Urology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Related Links:

ConclusionPUL is a well-tolerated, minimally invasive therapy for BPH that provides favorable and durable symptomatic, sexual health, and functional outcomes up to 24  months. Longer follow-up and randomized studies comparing to current standards are required to further confirm the long-term sustainability of PUL.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
ConclusionTRT could be considered for most men with LOH regardless of their history of prostate disease. However, a discussion about the risks and benefits of TRT is always advised, especially in men with PCa. Appropriate monitoring is mandatory.
Source: Andrology - Category: Urology & Nephrology Authors: Tags: REVIEW ARTICLE Source Type: research
In this study, we evaluated the effect of M. delavayi leaves aqueous extract (MD-T) and its fractions (MD-W and MD-E) on benign prostatic hyperplasia (BPH) in testosterone propionate (TP) induced rat model based on folk applications. The results showed that MD-T and MD-E could significantly reduce the prostate weight, prostate index, and serum level of prostate acid phosphatase (PAP) in BPH rats and improve the tissue morphology of the prostate. They mainly played roles in regulating the sex hormone level, reducing the levels of inflammatory factors and improving the antioxidant levels of prostate tissue. UPLC-Q-TOF-MS ana...
Source: Journal of Functional Foods - Category: Nutrition Source Type: research
ConclusionsPersistent PIS plays a central role in both the development and progression of LUTS/BPH. In men with LUTS/BPH who have a high chance of harbouring persistent PIS, HESr will not only improve LUTS, but also reduce (underlying) inflammation. Well-designed clinical studies, with a good level of evidence, are required to better evaluate the impact of BPH/LUTS medical therapies on persistent PIS.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
Abstract Bladder neck stenosis (BNS) after simple prostatectomy and vesicourethral anastomosis stenosis (VUAS) after radical prostatectomy for prostate cancer are common sequelae. However, the two entities differ in their pathology, anatomy and their surgical results. VUAS has an incidence of 0.2-28%. Commonly, VUAS occurs within the first 2 years after surgery. Initial therapy should be performed endourologically: dilatation, (laser) incision or resection. After three unsuccessful treatment attempts, open reconstruction should be considered. Different surgical approaches (abdominal, perineal, abdominoperinea...
Source: Der Urologe. Ausg. A - Category: Urology & Nephrology Authors: Tags: Urologe A Source Type: research
Condition:   Benign Prostatic Hyperplasia (BPH) Interventions:   Dietary Supplement: Placebo;   Dietary Supplement: Banana flower stamens extract Sponsor:   TCI Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, researchers from Austria, Germany and Switzerland investigated the effects of a proprietary oil-free hydroethanolic pumpkin seed extract on the symptoms of benign prostatic hyperplasia (BPH). Their findings were published in the Journal of Medicinal Food. The majority of men are affected by symptomatic BPH from a certain age. Extracts from medicinal...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
ConclusionsRoughly 1 in 5 patients undergoing lung resection develop POUR. Patients who developed POUR were more likely to not have a Foley catheter placed intraoperatively. However, patients who had POUR did not have worsened patient outcomes (urinary tract infections, length of stay, 30-day readmission).Graphical abstract
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
AbstractPurposeWith an aging population, cost containment and improved outcomes will be crucial for a sustainable healthcare ecosystem. Current data demonstrate great variation in payments for procedures and diagnostic workup of benign prostatic hyperplasia (BPH). To help determine the best financial value in BPH care, we sought to analyze the major drivers of total payments in BPH.Materials and methodsCommercial and Medicare claims from the Truven Health Analytics Markestscan® database for the Austin, Texas Metropolitan Service Area from 2012 to 2014 were queried for encounters with diagnosis and procedural codes rela...
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
AbstractGlaucoma is a leading cause of bilateral blindness. Phosphodiesterase type 5 inhibitors (PDE5Is; e.g. avanafil, sildenafil, tadalafil and vardenafil) may increase blood flow to the ciliary body, thereby elevating intraocular pressure and increasing the risk of glaucoma. PDE5Is are commonly used to treat erectile dysfunction, as well as benign prostatic hyperplasia (tadalafil) and pulmonary hypertension (sildenafil). Patients receiving PDE5Is require glaucoma education and ongoing screening, especially if they are taking a high dosage of a daily PDE5I or have risk factors for glaucoma (e.g. increased age, African-Am...
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
More News: Benign Prostatic Hyperplasia | Epidemiology | Health | Urology & Nephrology